Within a week of the Food and Drug Administration’s authorization of remdesivir as a COVID-19 treatment, clinicians are pushing the Trump administration to clarify how it is selecting which hospitals get access to the drug.
Shares of Gilead Sciences Inc. GILD, +0.18% [5], which developed remdesivir, edged up 0.2% in Thursday trades and are up 19.4% in 2020.
MORE… [6]